# Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

> **NCT00097500** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 69 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** exenatide
- **DRUG:** Insulin glargine
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00097500
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2015-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00097500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00097500, "Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00097500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*